Contract research news in brief
pharmafile | April 12, 2010 | News story | Research and Development |Â Â Ingenix, Medpace, NIB, NexMed, RDNIBÂ
A round-up of recent developments in the clinical research arena includes an expansion for NexMed’s pre-clinical division, acquisitions for Medpace and Ingenix, and new collaborations for Clinilabs and Ricerca.
US contract research organisation NexMed says it as expanded its facilities in San Diego to cater for a 20% increase in demand in 2009 at its pre-clinical research services unit Bio-Quant. Bio-Quant now has approximately 28,000 sq. ft of laboratory, vivarium and office space. The company said the stronger demand had come from “diversification of our service capabilities and entrance into new geographical markets.”
Clinilabs has added cardiac diagnostic tools to its portfolio of services through the signing of a service agreement with fellow US company NewCardio. Under the terms of the deal, Clinilabs has licensed NewCardio’s software for automated cardiac safety analyses in clinical trials, while NewCardio will help Clinilabs set up an electrocardiograph (ECG) core laboratory at its facility in Manhattan.
Medpace has acquired fellow CRO Symbios for an undisclosed amount. Symbios specialises in medical device research with a particular focus on pre-market, post-approval and post-market clinical trials. The company will continue to operate out of its headquarters in Minneapolis, and founder and chief executive Ryan Wilson will continue to run the business, which has been renamed Symbios Clinical.
Ingenix, the parent company of pharmaceutical services company i3, has added patient-reported outcomes (PRO) services to its portfolio with the recent acquisition of QualityMetric. Terms of the acquisition have not been disclosed. Brian Kelly, i3’s president, said that QualityMetric’s PRO capability “complements our clinical outcomes and medical expenditures research by providing a critical new component – patients’ assessments of their own health status.”
Ricerca Biosciences, a pre-clinical CRO, has forged an alliance with Life Science Partner of Japan in a bid to improve its presence in the Asian outsourcing market. Ricerca has been making a push into Asia recently, and recently spent $45 million buying MDS’ discovery and preclinical operations, which included a facility in Taiwan. LSP will be able to market Ricerca’s service portfolio to its customers in Japan, Korea and elsewhere in Asia.
Related Content
NHS England unveils digital roadmap
NHS England has laid out digital technology plans that it says will completely transform services …
Contract research news in brief
A round-up of news in the contract research sector, including new contracts for Medpace, Particle …
Contract research news in brief
A round-up of recent developments in the contract research sector, including updates from Parexel, Medpace, …
